Virios therapeutics announces publication of international patent for imc-2 covering antiviral treatment of long-covid

- new patent would extend coverage and expand potential value of virios' antiviral pipeline globally – - active long-covid characterized by immune dysfunction leading to recurrent herpesviruses reactivation - - published data indicates increased epstein-barr herpes virus in long-covid patients, highlighting potential for antiviral therapy to treat fatigue and other long-covid symptoms – atlanta, march 26, 2024 (globe newswire) -- virios therapeutics, inc.  (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including  fibromyalgia  (“fm”) and long-covid (“lc”), today announced that the world intellectual property organization (wipo) has published virios' global patent application titled “valacyclovir and celecoxib for the treatment of alzheimer's and covid-19”, which covers the use of imc-2, a proprietary combination of valacyclovir and celecoxib. this milestone enables virios to streamline the process for obtaining patent protection globally, representing a precursor to the national phase of patent examination by targeted countries across the globe.
VIRI Ratings Summary
VIRI Quant Ranking